Effect of Simvastatin on Cardiac Function
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01178710|
Recruitment Status : Completed
First Posted : August 10, 2010
Last Update Posted : July 26, 2012
|Condition or disease||Intervention/treatment||Phase|
|Rheumatic Heart Disease Congenital Heart Disease Aneurysm Heart Valve Disease||Drug: Simvastatin||Not Applicable|
Cardiac function is crucial for cardiac surgery. The mortality remains very high in patients with poor cardiac function preoperation, long surgical time, complicate or difficult surgical procedure or uncompleted corrected malformation currently. Thus, it is necessary to search other approaches to improve cardiac function for cardiac surgery patients in order to increase the success, decrease complication and mortality in cardiac surgery.
Although statin has been used to low cholesterol to prevent and treat coronary artery disease for many years, it has been reported that statin could protect endothelial function and cardiac function in coronary artery bypass graft. However, some results were controversy. Also, there is no clinical data available on statin cardiac protection during surgery in China where rheumatic heart disease is prevalence.Thus, it is necessary to perform a double blind, randomised clinical trial in China to determine whether statin can protect heart injury during heart surgery in China and what's its mechanism.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||151 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Outcomes Assessor)|
|Official Title:||The Cardiac Protective Effect of Simvastatin on Cardiac Surgery: a Double Blind, Randomised Clinical Trial|
|Study Start Date :||September 2010|
|Actual Primary Completion Date :||June 2011|
|Actual Study Completion Date :||July 2012|
20 mg per day, start at 5 days before surgery and continue for one year. For some congenital heart diseases which other drugs such as digoxin, antistone, furosemide were prescribed less than half year, simvastatin will be prescribed less than half year.
Other Name: simcor
No Intervention: untreated
- plasma troponin T level [ Time Frame: within the first 7 days after surgery ]The investigator will measure the plasma troponin T level in several time points before and after surgery in each patient.
- the index of B ultrasound on heart [ Time Frame: one year after surgery ]Each patient will be followed up and checked with B ultrasound on heart in 1,3,6 and 12 months after surgery. The index of B ultrasound on heart, such as ejection fraction, the diameter of left ventricle, will be measured
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01178710
|The First Affiliated Hospital, Sun Yat-sen University|
|Guangzhou, Guangdong, China, 510080|
|Principal Investigator:||Jing-song Ou, MD,PhD||The Frist Affiliated Hospital, Sun Yat-sen University|